|
USP30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.07269999958393E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.56505999999723E-05 |
| Normal-vs-Stage2 |
1.106610E-01 |
| Normal-vs-Stage3 |
2.65079999950402E-07 |
| Normal-vs-Stage4 |
6.36929999853209E-08 |
| Stage1-vs-Stage2 |
3.346300E-02 |
| Stage1-vs-Stage3 |
1.252810E-01 |
| Stage1-vs-Stage4 |
4.080300E-02 |
| Stage2-vs-Stage3 |
3.795300E-03 |
| Stage2-vs-Stage4 |
1.264400E-03 |
| Stage3-vs-Stage4 |
4.136600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.46780000048952E-07 |
| Normal-vs-AfricanAmerican |
1.761940E-02 |
| Normal-vs-Asian |
7.220300E-04 |
| Caucasian-vs-AfricanAmerican |
3.298800E-01 |
| Caucasian-vs-Asian |
1.233180E-01 |
| AfricanAmerican-vs-Asian |
9.130000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.89400000000428E-06 |
| Normal-vs-Female |
2.11009999995238E-06 |
| Male-vs-Female |
8.740800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.63010000018427E-07 |
| Normal-vs-Age(41-60Yrs) |
2.424900E-04 |
| Normal-vs-Age(61-80Yrs) |
1.57705999999092E-05 |
| Normal-vs-Age(81-100Yrs) |
4.218900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.454400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.321000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.223400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.213400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.354000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.666400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.66869999999042E-05 |
| Classical-VS-Follicular |
2.002100E-02 |
| Classical-VS-Other |
6.573200E-01 |
| Classical-VS-Normal |
1.45640000004388E-06 |
| Tall-VS-Follicular |
1.10220000015815E-07 |
| Tall-VS-Other |
9.387600E-02 |
| Tall-VS-Normal |
4.59059457114108E-11 |
| Follicular-VS-Other |
2.681200E-01 |
| Follicular-VS-Normal |
5.282200E-02 |
| Other-VS-Normal |
2.420000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.010200E-04 |
| Normal-vs-N1 |
7.12220005194553E-09 |
| N0-vs-N1 |
2.516900E-03 |
|
|
